Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Santhera Pharmaceuticals Holding (0QN1) Share Price & Analysis

0QN1 Stock Chart & Stats

CHF 15.25-CHF 0.63(-3.97%)
At close: 4:30 PM GMT
CHF 14CHF 15CHF 16CHF 173 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
CHF 15.22 - CHF 15.26
52-Week Range
CHF 10.16 - CHF 18.72
Previous Close
CHF 15.88
Volume
12.82K
Average Volume (3M)
3,438
Market Cap
CHF 234.69M
Enterprise Value
CHF 271.86M
Total Cash (Recent Filing)
CHF 41.77M
Total Debt (Recent Filing)
CHF 41.27M
Price to Earnings (P/E)
―
Beta
0.93
Next Earnings
Apr 29, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Commercial Growth

Rapid revenue and product-sales growth indicates accelerating adoption of AGAMREE and expanding commercial reach. If sustained, this momentum can improve operating leverage, support reinvestment in rare-disease opportunities, and strengthen Santhera’s position with prescribers and partners over the coming quarters.

Expanding Market Access

Broadening launches and reimbursement progress create a larger addressable commercial base for the company’s lead product. Expansion across major European markets, supported by distributor coverage, can diversify revenue sources and provide a durable foundation for continued product adoption beyond the initial launch markets.

Strategic Licensing Platform

The Nxera partnership extends Santhera’s geographic reach without requiring the company to commercialize every market directly. Upfront cash, potential milestones and royalties can provide non-linear revenue opportunities while validating AGAMREE’s international potential and preserving participation in future regional growth.

Bears Say

Negative Equity And Higher Debt

Negative equity combined with materially higher debt weakens financial resilience and reduces flexibility to absorb execution setbacks. The capital structure may constrain investment choices and increase dependence on successful commercialization, particularly while the company continues transitioning toward sustainable profitability.

Persistent Cash Burn

Recurring operating and free-cash-flow deficits show that the business has not yet consistently funded itself from operations. Continued cash burn can limit Santhera’s ability to invest in additional assets or absorb delays, making progress toward durable cash generation an important condition for financial stability.

Pricing And Reimbursement Pressure

Lower German pricing could reduce revenue and margins in an important market, while delayed French reimbursement postpones access to another major opportunity. Together, these issues may temper near-term commercial conversion and make the company’s growth targets more dependent on other markets and partners.

Santhera Pharmaceuticals Holding News

0QN1 FAQ

What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest share price was CHF10.16 and its highest was CHF18.72 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is CHF234.69M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Santhera Pharmaceuticals Holding released its earnings results on Sep 30, 2026. The company reported -CHF1.5 earnings per share for the quarter, missing the consensus estimate of CHF0.17 by -CHF1.67.
Is Santhera Pharmaceuticals Holding overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 15,941,051 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Santhera Pharmaceuticals Holding reported an EPS of -CHF1.5 in its last earnings report, missing expectations of CHF0.17. Following the earnings report the stock price went up 2.933%.
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in GB:0QN1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology